drugset / Trial / NCT02245230
Cardiovascular Effects of Angiotensin (1-7) in Essential Hypertension
RandomizedCrossoverOpen-labelOther
Summary
The purpose of this study is to better understand the cardiovascular effects of the vasodilatory peptide Angiotensin (1-7) in human hypertension. In this study, the investigators will test the hypothesis that systemic Angiotensin (1-7) infusion produces negligible effects with intact baroreceptors, and that the cardiovascular effects of this peptide are unmasked following elimination of baroreflex buffering.
Timeline
- Start
- 2015-01
- Primary completion
- 2023-12
- Completion
- 2023-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Trimethaphan | Small molecule | 5 mg | Intravenous |
| Subject | talfirastide | Peptide | 0.5 unknown | Intravenous |
| Subject | talfirastide | Peptide | 20 unknown | Intravenous |
| Background | Phenylephrine | Small molecule | 0.1 ug/kg | Intravenous |
| Background | Phenylephrine | Small molecule | 0.5 ug/kg | Intravenous |